João Pedro Ferreira1,2, Marco Metra3, Ify Mordi4, John Gregson5, Jozine M Ter Maaten6, Jasper Tromp6, Stefan D Anker7,8, Kenneth Dickstein9,10, Hans L Hillege6, Leong L Ng11, Dirk J van Veldhuisen6, Chim C Lang4, Adriaan A Voors6, Faiez Zannad1. 1. INSERM, Centre d'Investigations Cliniques Plurithématique 1433, Université de Lorraine, CHRU de Nancy and F-CRIN INI-CRCT, Nancy, France. 2. Cardiovascular Research and Development Unit, Department of Physiology and Cardiothoracic Surgery, Faculty of Medicine, University of Porto, Porto, Portugal. 3. Department of Medical and Surgical Specialties, Radiological Sciences and Public Health, University of Brescia, Brescia, Italy. 4. Division of Molecular and Clinical Medicine, Ninewells Hospital and Medical School, University of Dundee, Dundee, UK. 5. Department of Biostatistics, London School of Hygiene & Tropical Medicine, London, UK. 6. Department of Cardiology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands. 7. Division of Cardiology and Metabolism, Department of Cardiology (CVK), and Berlin-Brandenburg Center for Regenerative Therapies (BCRT), German Centre for Cardiovascular Research (DZHK) partner site Berlin, Charité Universitätsmedizin Berlin, Germany. 8. Department of Cardiology and Pneumology, University Medicine Göttingen (UMG), Göttingen, Germany. 9. Department of Internal Medicine, University of Bergen, Bergen, Norway. 10. Department of Cardiology, Stavanger University Hospital, Stavanger, Norway. 11. Department of Cardiovascular Sciences, University of Leicester, Glenfield Hospital, Leicester, UK, and NIHR Leicester Biomedical Research Centre, Glenfield Hospital, Leicester, UK.
Abstract
INTRODUCTION: Patients with symptomatic heart failure (HF) require additive therapies and have a poor prognosis. However, patient characteristics and clinical outcome between HF patients treated in the outpatient setting vs. those who are hospitalized remain scarce. METHODS AND RESULTS: The BIOlogy Study to TAilored Treatment in Chronic Heart Failure (BIOSTAT-CHF) included 2516 patients with symptoms and/or signs of HF: 1694 as inpatients and 822 as outpatients. Compared to ambulatory HF patients, inpatients had higher heart rate, urea, N-terminal pro-brain natriuretic peptide, lower blood pressure, lower estimated glomerular filtration rate, sodium, potassium, high-density lipoprotein cholesterol, had more often peripheral oedema, diabetes, anaemia, and were less often treated with beta-blockers and angiotensin-converting enzyme inhibitors (ACEi). Outpatients had a more frequent history of HF hospitalization and received more frequently beta-blockers and/or ACEi/angiotensin receptor blockers up-titrated to target doses (P < 0.001). Inpatients had higher rates of the primary outcome of death or HF hospitalization: incidence rate per 100 person-years of 33.4 [95% confidence interval (CI) 31.1-35.9] for inpatients vs. 18.5 (95% CI 16.4-21.0) for outpatients; adjusted hazard ratio 1.24 (95% CI 1.07-1.43). Subdividing patients into low, intermediate and high-risk categories, the primary outcome event rates were 14.3 (95% CI 12.3-16.7), 36.6 (95% CI 32.2-41.5), and 71.3 (95% CI 64.4-79.0) for inpatients vs. 8.4 (95% CI 6.6-10.6), 29.8 (95% CI 24.5-36.2), and 43.3 (95% CI 34.7-54.0) for outpatients, respectively. These findings were externally replicated. CONCLUSIONS: Marked differences were observed between inpatients and outpatients with HF. Overall, inpatients were sicker and had higher event rates. However, a substantial proportion of outpatients had similar or higher event rates compared to inpatients. These findings suggest that HF outpatients also have poor prognosis and may be the focus of future trials.
INTRODUCTION:Patients with symptomatic heart failure (HF) require additive therapies and have a poor prognosis. However, patient characteristics and clinical outcome between HF patients treated in the outpatient setting vs. those who are hospitalized remain scarce. METHODS AND RESULTS: The BIOlogy Study to TAilored Treatment in Chronic Heart Failure (BIOSTAT-CHF) included 2516 patients with symptoms and/or signs of HF: 1694 as inpatients and 822 as outpatients. Compared to ambulatory HF patients, inpatients had higher heart rate, urea, N-terminal pro-brain natriuretic peptide, lower blood pressure, lower estimated glomerular filtration rate, sodium, potassium, high-density lipoprotein cholesterol, had more often peripheral oedema, diabetes, anaemia, and were less often treated with beta-blockers and angiotensin-converting enzyme inhibitors (ACEi). Outpatients had a more frequent history of HF hospitalization and received more frequently beta-blockers and/or ACEi/angiotensin receptor blockers up-titrated to target doses (P < 0.001). Inpatients had higher rates of the primary outcome of death or HF hospitalization: incidence rate per 100 person-years of 33.4 [95% confidence interval (CI) 31.1-35.9] for inpatients vs. 18.5 (95% CI 16.4-21.0) for outpatients; adjusted hazard ratio 1.24 (95% CI 1.07-1.43). Subdividing patients into low, intermediate and high-risk categories, the primary outcome event rates were 14.3 (95% CI 12.3-16.7), 36.6 (95% CI 32.2-41.5), and 71.3 (95% CI 64.4-79.0) for inpatients vs. 8.4 (95% CI 6.6-10.6), 29.8 (95% CI 24.5-36.2), and 43.3 (95% CI 34.7-54.0) for outpatients, respectively. These findings were externally replicated. CONCLUSIONS: Marked differences were observed between inpatients and outpatients with HF. Overall, inpatients were sicker and had higher event rates. However, a substantial proportion of outpatients had similar or higher event rates compared to inpatients. These findings suggest that HF outpatients also have poor prognosis and may be the focus of future trials.
Authors: Javed Butler; Milton Packer; Stephen J Greene; Mona Fiuzat; Stefan D Anker; Kevin J Anstrom; Peter E Carson; Lauren B Cooper; Gregg C Fonarow; Adrian F Hernandez; James L Januzzi; Mariell Jessup; Rita R Kalyani; Sanjay Kaul; Mikhail Kosiborod; JoAnn Lindenfeld; Darren K McGuire; Marc S Sabatine; Scott D Solomon; John R Teerlink; Muthiah Vaduganathan; Clyde W Yancy; Norman Stockbridge; Christopher M O'Connor Journal: Circulation Date: 2019-12-16 Impact factor: 29.690
Authors: Suzanne V Arnold; Philip G Jones; Michael Beasley; Jeanine Cordova; Abhinav Goyal; Gregg C Fonarow; Leo Seman Journal: Cardiovasc Diabetol Date: 2020-12-12 Impact factor: 9.951
Authors: Eric Wierda; Cathelijne Dickhoff; Martin Louis Handoko; Liane Oosterom; Wouter Emmanuel Kok; Y de Rover; B A J M de Mol; Loek van Heerebeek; Jutta Maria Schroeder-Tanka Journal: ESC Heart Fail Date: 2020-03-11